logo-loader
HealthPharma & Biotech
viewAbcam

Abcam forecasts double digit revenue growth for full-year as it sees product growth across the board

The AIM-listed antibody supplier said it expected revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10%

Antibodies
Revenue from custom products and licensing also grew by 18% during the year

Abcam PLC (LON:ABC) said it expects double-digit growth in its full-year results following strong income growth across all of its product categories.

The AIM-listed antibody supplier said it expects revenue for the full year to grow by 10.7% in constant currency, with catalogue growth of “over” 10% underpinning the rise after all product categories continued to grow ahead of its market.

READ: Abcam raises revenue guidance after Roche deal

The firm added that revenue from custom products and licensing, which accounted for around 7% of total revenue, also grew by 18% during the year.

Abcam also said it expected margins to be in line with the previous year's figure of 70.1%, while margins for adjusted earnings before interest, taxes, depreciation and amortisation were forecast to be in line with expectations.

In a note to clients, analysts at City broker Numis upped their target price for the firm to 1,380p from 1,316p, citing that the strong growth forecasts could “indicate the emergence of a new fourth double-digit growth engine in the business”.

In lunchtime trading Thursday, Abcam shares were down 4.8% at 1,322p.

Quick facts: Abcam

Price: 1150 GBX

AIM:ABC
Market: AIM
Market Cap: £2.37 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Panther Metals set up for its next strategic move with an 'enviable'...

Panther Metals plc's (LON:PALM) Darren Hazelwood and Kerim Sener introduce the explorer to Proactive London's Andrew Scott. In Canada recent field activities have returned some 'exceptional' results including significant soil gold anomalies in four major target areas. Meanwhile in...

12 hours, 49 minutes ago

RNS

Holding(s) in Company

2 weeks, 1 day ago

Director/PDMR Shareholding

2 weeks, 1 day ago

Total Voting Rights

2 weeks, 2 days ago

Annual Financial Report

2 weeks, 3 days ago

Director/PDMR Shareholding

1 month, 1 day ago

2 min read